BRPI0610125B8 - composição farmacêutica, kit e utilização de uma composição - Google Patents

composição farmacêutica, kit e utilização de uma composição

Info

Publication number
BRPI0610125B8
BRPI0610125B8 BRPI0610125A BRPI0610125A BRPI0610125B8 BR PI0610125 B8 BRPI0610125 B8 BR PI0610125B8 BR PI0610125 A BRPI0610125 A BR PI0610125A BR PI0610125 A BRPI0610125 A BR PI0610125A BR PI0610125 B8 BRPI0610125 B8 BR PI0610125B8
Authority
BR
Brazil
Prior art keywords
composition
pharmaceutical composition
kit
pharmaceutical
ionone
Prior art date
Application number
BRPI0610125A
Other languages
English (en)
Portuguese (pt)
Inventor
Remmal Adnane
Original Assignee
Advanced Scient Developments
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Scient Developments filed Critical Advanced Scient Developments
Publication of BRPI0610125A2 publication Critical patent/BRPI0610125A2/pt
Publication of BRPI0610125B1 publication Critical patent/BRPI0610125B1/pt
Publication of BRPI0610125B8 publication Critical patent/BRPI0610125B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0610125A 2005-05-13 2006-05-15 composição farmacêutica, kit e utilização de uma composição BRPI0610125B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2005/001313 WO2006120494A1 (fr) 2005-05-13 2005-05-13 Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l’eugenol, le borneol et les carvacrol
IBPCT/IB2005/001313 2005-05-13
PCT/IB2006/001350 WO2006120567A2 (fr) 2005-05-13 2006-05-15 Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l'eugenol, le borneol et le carvacrol

Publications (3)

Publication Number Publication Date
BRPI0610125A2 BRPI0610125A2 (pt) 2012-09-25
BRPI0610125B1 BRPI0610125B1 (pt) 2020-08-11
BRPI0610125B8 true BRPI0610125B8 (pt) 2021-05-25

Family

ID=35427275

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0610125A BRPI0610125B8 (pt) 2005-05-13 2006-05-15 composição farmacêutica, kit e utilização de uma composição

Country Status (13)

Country Link
US (1) US20080214518A1 (enExample)
EP (1) EP1879655B1 (enExample)
JP (1) JP5410748B2 (enExample)
CN (3) CN102319246B (enExample)
BR (1) BRPI0610125B8 (enExample)
CA (1) CA2606875C (enExample)
DK (1) DK1879655T3 (enExample)
EA (1) EA014069B1 (enExample)
ES (1) ES2530963T3 (enExample)
MA (1) MA29606B1 (enExample)
PT (1) PT1879655E (enExample)
TN (1) TNSN07424A1 (enExample)
WO (2) WO2006120494A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2918571B1 (fr) * 2007-07-10 2013-01-11 Aroma Tech Compositions antibiotiques a base d'huiles essentielles prophylaxie et traitement d'infections nosocomiales
WO2009052629A1 (en) * 2007-10-26 2009-04-30 Chemaphor Inc. Compositions and methods for enhancing immune response
FR2925334A1 (fr) * 2007-12-21 2009-06-26 Ceva Sante Animale Sa Nouvelles compositions antibacteriennes
CA2975313C (en) 2009-04-30 2020-06-30 Avivagen Inc. Methods and compositions for improving the health of animals
CA2801143C (en) 2009-09-24 2017-09-26 Unilever Plc Disinfecting agent comprising eugenol, terpineol and thymol
MX2013006435A (es) 2010-12-07 2013-07-03 Unilever Nv Composicion para cuidado oral.
US9693941B2 (en) 2011-11-03 2017-07-04 Conopco, Inc. Liquid personal wash composition
WO2013083592A1 (en) 2011-12-06 2013-06-13 Unilever N.V. Antimicrobial composition
CN102670619B (zh) * 2012-05-08 2014-02-19 广东药学院 一种头孢氨苄冰片组合物
CN102670598B (zh) * 2012-05-08 2014-07-16 广东药学院 一种青霉素冰片组合物在制备抗菌药物中的应用
CN103146255B (zh) * 2013-02-25 2014-07-09 厦门吉宏包装科技有限公司 一种抑菌驱螨印刷底油母液和由母液制作的印刷底油及其制备方法
US20140336271A1 (en) * 2013-05-07 2014-11-13 Kemin Industries, Inc. Antimicrobial Compositions Containing Carvacrol and Thymol
FR3025719A1 (fr) 2014-09-15 2016-03-18 Septeos Antimicrobiens potentialises
FR3025718A1 (fr) 2014-09-15 2016-03-18 Septeos Antimicrobiens potentialises
WO2016081594A1 (en) * 2014-11-19 2016-05-26 The General Hospital Corporation System and method for photo-dynamic procedure
CN107530397A (zh) * 2014-12-18 2018-01-02 赫尔普百治疗有限公司 新型组合和用途
WO2016097755A1 (en) * 2014-12-18 2016-06-23 Helperby Therapeutics Limited Antimicrobial combinations and their use in the treatment of microbial infection
CN109512999B (zh) * 2016-03-04 2022-05-10 广州英赛特生物技术有限公司 含氧碳氢衍生物的脂肪醇作为多粘菌素的协同增效剂的应用
FR3048612B1 (fr) 2016-03-14 2020-10-02 Septeos Tulathromycine potentialisee
MA44286A (fr) 2016-06-02 2019-01-09 Advanced Scient Developements Formulation pharmaceutique de cinéol et d'amoxicilline
GB201904963D0 (en) * 2019-04-08 2019-05-22 Anpario Plc Composition for reducing antimicrobial resistance
ES2986948T3 (es) 2019-12-04 2024-11-13 Pranarom Int S A Procedimiento de transformación de un aceite esencial
KR102848354B1 (ko) * 2023-02-13 2025-08-21 경상국립대학교산학협력단 테트라사이클린계 항생제와 시너지 효과를 가지는 바닐린 또는 카바크롤을 유효성분으로 포함하는 조성물 및 이의 용도

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4317775A (en) * 1980-01-07 1982-03-02 Hoffmann-La Roche Inc. Amoxicillin derivatives
US5213615A (en) * 1986-10-11 1993-05-25 Ivoclar Ag Dental material and method for the control of caries and paradentitis
DE3634697A1 (de) * 1986-10-11 1988-04-21 Dentaire Ivoclar Ets Dentalwerkstoff zur bekaempfung von karies und parodontose
US5801153A (en) * 1991-09-13 1998-09-01 Badaway; Mohammed A. Method of enhancing the antimicrobial properties of antibacterial antibiotics to massively control and prevent bacterial, fungal, and viral diseases in plants
FR2697133B1 (fr) * 1992-10-28 1995-01-13 Transbiotech Composition biocide et/ou biostatique et ses applications.
US5308873A (en) * 1992-12-18 1994-05-03 Doyle E. Chastain Method of killing yeast and fungi with carveol
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
CA2224227A1 (en) * 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US6319507B1 (en) * 1997-05-02 2001-11-20 Kobo Products, Inc. Agar gel bead composition and method
US6025400A (en) * 1998-08-24 2000-02-15 Marco Polo Technologies Compositions for treatment of antibiotic-resistant gram-positive bacterial infections and methods for using and preparing the same
SE9901733L (sv) * 1999-05-12 2000-11-13 Akzo Nobel Nv En komposition innehållande karvakrol och tymol för användning som bactericid
US6414036B1 (en) * 1999-09-01 2002-07-02 Van Beek Global/Ninkov Llc Composition for treatment of infections of humans and animals
US6495512B1 (en) * 2000-06-23 2002-12-17 International Flavors & Fragrances Inc. Salicylaldehyde-containing composition having antimicrobial and fragrancing properties and process for using same
WO2002028382A1 (en) * 2000-10-06 2002-04-11 Van Beek, Ron Compositions for injection or intravenous administration for the treatment of internal infection or inflammation in humans and animals
US6787568B1 (en) * 2000-11-27 2004-09-07 Phoenix Scientific, Inc. Antibiotic/analgesic formulation and a method of making this formulation
EP1230917A1 (de) * 2001-02-08 2002-08-14 Vectron Therapeutics AG Invasomen zur Therapie von Erkrankungen, ihre Herstellung und Verwendung
US6585963B1 (en) * 2001-02-15 2003-07-01 Watson Pharmaceuticals, Inc. Nail compositions and methods of administering same
WO2003049726A1 (en) * 2001-12-07 2003-06-19 Eden Research Plc Respiratory infection prevention and treatment with terpene-containing compositions
US20030225003A1 (en) * 2002-04-18 2003-12-04 Dusan Ninkov Antimicrobial therapeutic compositions for oral and topical use
EP1562543A1 (en) * 2002-11-21 2005-08-17 J.P.M.E.D. Ltd. Compositions for treating infected skin and mucous membrane comprising an anti-microbial agent and an essential oil
CN1744905A (zh) * 2002-12-10 2006-03-08 百敖新纳斯有限公司 局部抗感染制剂
US20040151771A1 (en) * 2003-02-04 2004-08-05 Gin Jerry B. Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth
SI2338332T1 (sl) * 2004-05-20 2014-06-30 Eden Research Plc Votli delec glukana ali votli delec stene celice, ki enkapsulira komponento terpena

Also Published As

Publication number Publication date
EA014069B1 (ru) 2010-08-30
TNSN07424A1 (fr) 2009-03-17
CN102319246A (zh) 2012-01-18
CN101175531B (zh) 2011-09-07
CA2606875C (fr) 2015-12-15
DK1879655T3 (en) 2015-02-23
BRPI0610125B1 (pt) 2020-08-11
CN103356612A (zh) 2013-10-23
MA29606B1 (fr) 2008-07-01
BRPI0610125A2 (pt) 2012-09-25
ES2530963T3 (es) 2015-03-09
CN103356612B (zh) 2015-04-15
WO2006120567A2 (fr) 2006-11-16
EA200702483A1 (ru) 2008-04-28
WO2006120494A1 (fr) 2006-11-16
CN102319246B (zh) 2013-07-17
PT1879655E (pt) 2015-02-24
CA2606875A1 (fr) 2006-11-16
EP1879655A2 (fr) 2008-01-23
WO2006120567A3 (fr) 2007-08-23
EP1879655B1 (fr) 2014-11-26
JP5410748B2 (ja) 2014-02-05
US20080214518A1 (en) 2008-09-04
CN101175531A (zh) 2008-05-07
JP2008540507A (ja) 2008-11-20

Similar Documents

Publication Publication Date Title
BRPI0610125B8 (pt) composição farmacêutica, kit e utilização de uma composição
BRPI0610132B8 (pt) composição farmacêutica, kit e utilização de uma composição
ES3041966T3 (en) Use of cannabidiol in combination with norfenfluramine or fenfluramine in the treatment of epilepsy
PE20091394A1 (es) Un compuesto de alfa-(n-sulfonamido) acetamida con un inhibidor de produccion de peptido beta amiloide
CL2007002641A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
CL2008000593A1 (es) Uso de compuestos derivados de heterociclos sustituidos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad aterosclerotica de las arterias entre otras enfermedades.
UY30712A1 (es) Nuevos derivados de 1, 4-benzotiepina-1, 1-dioxido sustituidos con fluor, método para su preparacion, productos farmacéuticos que comprenden estos compuestos y su uso.
UY29983A1 (es) Derivados de 4-amino-pirrolotriazina sustituida utiles para el tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogenesis
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
MX384206B (es) Formulaciones de inhibidores de dpp iv
CL2008001868A1 (es) Compuestos derivados de n-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas; composicion farmaceutica que comprende a dicho compuesto; y uso para el tratamiento de enfermedades inflamatorias del intestino, enfermedad alergica
BRPI0512792A (pt) formas cristalinas sólidas de cloridrato de ( - ) - (1r, 2r) - 3 - (3-dimetilamino-1-etil-2-metilpropil) - fenol
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
CU23614B7 (es) Forma cristalina beta del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
BRPI0513812B8 (pt) método para produzir uma composição líquida que compreende 13c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radical
CL2008000910A1 (es) Proteina de fusion que comprende una proteina que corta el peptido beta amiloide; composicion farmaceutica que la comprende, y su uso para prevenir y/o tratar enfermedades relacionadas con el peptido beta amiloide.
BRPI0618380A2 (pt) combinação farmacêutica e seu uso
BRPI0518904A2 (pt) formulaÇÕes de nepafenac tàpicas
UY30215A1 (es) Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones
EA200702486A1 (ru) Противовирусная, противоопухолевая или противопаразитарная фармацевтическая композиция и ее применение
ECSP066883A (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes
DOP2010000088A (es) Compuesto inhibidor de fosforilasa de glicógeno y composición farmacéutica del mismo.
CL2009000599A1 (es) Compuestos derivados de 4,5-dihidro-1h-pirazol(4,3-g)benzotiazol sustituidos; composicion farmaceutica; utiles para el tratamiento y prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes, entre otras.
UY31143A1 (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B15K Others concerning applications: alteration of classification

Ipc: A61K 45/06 (2006.01), A61P 31/04 (2006.01), A61K 3

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/08/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/05/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF